- Home
- RCKT vs PRTA Comparison
RCKT vs PRTA Comparison
Compare RCKT & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCKT
- PRTA
- Stock Information
- Founded
- RCKT 1999
- PRTA 2012
- Country
- RCKT United States
- PRTA Ireland
- Employees
- RCKT N/A
- PRTA N/A
- Industry
- RCKT Biotechnology: Pharmaceutical Preparations
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- RCKT Health Care
- PRTA Health Care
- Exchange
- RCKT Nasdaq
- PRTA Nasdaq
- Market Cap
- RCKT 328.6M
- PRTA 472.1M
- IPO Year
- RCKT N/A
- PRTA N/A
- Fundamental
- Price
- RCKT $3.28
- PRTA $8.20
- Analyst Decision
- RCKT Buy
- PRTA Buy
- Analyst Count
- RCKT 13
- PRTA 10
- Target Price
- RCKT $12.96
- PRTA $14.86
- AVG Volume (30 Days)
- RCKT 6.0M
- PRTA 1.2M
- Earning Date
- RCKT 08-07-2025
- PRTA 08-04-2025
- Dividend Yield
- RCKT N/A
- PRTA N/A
- EPS Growth
- RCKT N/A
- PRTA N/A
- EPS
- RCKT N/A
- PRTA N/A
- Revenue
- RCKT N/A
- PRTA $10,341,000.00
- Revenue This Year
- RCKT N/A
- PRTA N/A
- Revenue Next Year
- RCKT $108.43
- PRTA $389.77
- P/E Ratio
- RCKT N/A
- PRTA N/A
- Revenue Growth
- RCKT N/A
- PRTA N/A
- 52 Week Low
- RCKT $2.19
- PRTA $4.32
- 52 Week High
- RCKT $22.01
- PRTA $22.83
- Technical
- Relative Strength Index (RSI)
- RCKT 51.17
- PRTA 58.73
- Support Level
- RCKT $2.88
- PRTA $8.05
- Resistance Level
- RCKT $3.74
- PRTA $8.73
- Average True Range (ATR)
- RCKT 0.27
- PRTA 0.38
- MACD
- RCKT 0.02
- PRTA -0.05
- Stochastic Oscillator
- RCKT 35.43
- PRTA 47.62
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.